Bullish option flow detected in Crispr Therapeutics with 1,714 calls trading, 1.1x expected, and implied vol increasing over 1 point to 57.50%. Jan-25 80 calls and 8/30 weekly 43 puts are the most active options, with total volume in those strikes near 1,100 contracts. The Put/Call Ratio is 0.37. Earnings are expected on November 4th.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
- Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital
- Crispr Therapeutics price target lowered to $59 from $60 at Stifel
- Crispr Therapeutics price target lowered to $59 from $67 at Barclays
- Crispr Therapeutics price target lowered to $94 from $112 at Chardan